Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Changes in activity of metalloproteinases 2 and 9 in rat liver in experimental model of cholestasis taking into account its duration and assessment of selected features
1
Zakład Medycyny Sportowej i Fizjologii Wysiłku Fizycznego, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach / Department of Sports Medicine and Physiology of Physical Effort, Faculty of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland
2
Centrum Medycyny Doświadczalnej, Wydział Nauk Medycznych w Katowicach, Śląski Uniwersytet Medyczny w Katowicach / Department of Experimental Medicine, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Corresponding author
Natalia Białoń
Zakład Medycyny Sportowej i Fizjologii Wysiłku Fizycznego, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, ul. Medyków 12, 40-752 Katowice
Zakład Medycyny Sportowej i Fizjologii Wysiłku Fizycznego, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny w Katowicach, ul. Medyków 12, 40-752 Katowice
Ann. Acad. Med. Siles. 2023;77:95-107
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Cholestasis, otherwise known as bile stasis, occurs when the flow of bile is blocked. There are currently two types of cholestasis: extrahepatic and intrahepatic. The factors causing cholestasis include alcoholic and non-alcoholic fatty liver disease, infections, biliary tract disease, biliary tract tumours or pancreatic disease. The aim of this study was to assess the features of cholestasis and changes in the activity of metalloproteinases 2 and 9.
Material and methods:
The study material consisted of 36 male rats of the Sprague-Dawley strain weighing 350–420 g. The animals were divided into 3 study groups and 3 control groups, each with 6 animals. An extrahepatic cholestasis model was induced in the study groups. In both groups, the animals were reoperated on consecutively after 3, 7 and 14 days. The activity of the selected metalloproteinases was assessed by zymography. The histopathological preparations were then assessed microscopically, evaluating the characteristic features of cholestasis in rat liver.
Results:
All the groups were statistically analysed using the Kruskal-Wallis test for non-parametric values. Computerised densitometric analysis of the zymography results obtained from the collected material showed the presence of MMP-2 and MMP-9 activity. Statistically significant differences were determined for MMP-2, where its activity was found to be elevated in groups I C, III C (*p < 0.05) compared to the control groups. An increasing trend was observed.
Conclusions:
MMP-2 activity increases with the duration of cholestasis. The results of the histopathological analysis of selected features of cholestasis showed that significantly higher scores were obtained by the animals in the experimental cholestasis model.
Cholestasis, otherwise known as bile stasis, occurs when the flow of bile is blocked. There are currently two types of cholestasis: extrahepatic and intrahepatic. The factors causing cholestasis include alcoholic and non-alcoholic fatty liver disease, infections, biliary tract disease, biliary tract tumours or pancreatic disease. The aim of this study was to assess the features of cholestasis and changes in the activity of metalloproteinases 2 and 9.
Material and methods:
The study material consisted of 36 male rats of the Sprague-Dawley strain weighing 350–420 g. The animals were divided into 3 study groups and 3 control groups, each with 6 animals. An extrahepatic cholestasis model was induced in the study groups. In both groups, the animals were reoperated on consecutively after 3, 7 and 14 days. The activity of the selected metalloproteinases was assessed by zymography. The histopathological preparations were then assessed microscopically, evaluating the characteristic features of cholestasis in rat liver.
Results:
All the groups were statistically analysed using the Kruskal-Wallis test for non-parametric values. Computerised densitometric analysis of the zymography results obtained from the collected material showed the presence of MMP-2 and MMP-9 activity. Statistically significant differences were determined for MMP-2, where its activity was found to be elevated in groups I C, III C (*p < 0.05) compared to the control groups. An increasing trend was observed.
Conclusions:
MMP-2 activity increases with the duration of cholestasis. The results of the histopathological analysis of selected features of cholestasis showed that significantly higher scores were obtained by the animals in the experimental cholestasis model.
REFERENCES (52)
1.
Hartleb M., Krawczyk M., Wunsch E., Raszeja-Wyszomirska J., Cichoż-Lach H., Żorniak M. i wsp. Choroby cholestatyczne u dorosłych – wytyczne postępowania Sekcji Hepatologicznej Polskiego Towarzystwa Gastroenterologii (PTG-E). Gastroenterol. Prakt. 2018; 2: 5–32.
2.
Li M., Cai S.Y., Boyer J.L. Mechanisms of bile acid mediated inflammation in the liver. Mol. Aspects Med. 2017; 56: 45–53, doi: 10.1016/j.mam.2017.06.001.
3.
Pollock G., Minuk G.Y. Diagnostic considerations for cholestatic liver disease. J. Gastroenterol. Hepatol. 2017; 32(7): 1303–1309, doi: 10.1111/jgh.13738.
4.
Shah R., John S. Cholestatic Jaundice. StatPearls [Internet], 2021 Jul 19. Treasure Island (FL): StatPearls Publishing; 2022.
5.
Romański K. Cholestaza u człowieka i zwierząt: występowanie, przyczyny, mechanizmy. Życie Wet. 2010; 85(1): 56–59.
6.
Kozicki I. Chirurgia dróg żółciowych. Postępy w chirurgii w 2011 roku. Med. Prakt. Chir. 2012; 2: 19–25.
7.
Mortelé K.J., Wiesner W., Cantisani V., Silverman S.G., Ros P.R. Usual and unusual causes of extrahepatic cholestasis: assessment with magnetic resonance cholangiography and fast MRI. Abdom. Imaging 2004; 29(1): 87–99, doi: 10.1007/s00261-003-0062-6.
8.
Padillo J., Puente J., Gómez M., Dios F., Naranjo A., Vallejo J.A. i wsp. Improved cardiac function in patients with obstructive jaundice after internal biliary drainage: hemodynamic and hormonal assessment. Ann. Surg. 2001; 234(5): 652–656, doi: 10.1097/00000658-200111000-00010.
9.
Krupa Ł., Staroń R., Gutkowski K. Drenaż dróg żółciowych w asyście endosonografii – evidence based medicine. Gastroenterol. Klin. 2019; 11(1): 29–32.
10.
Chu J., He S., Ke Y., Liu X., Wang P., Zhang W. i wsp. The effect of preoperative biliary drainage with or without pancreatic stenting on complications after pancreatoduodenectomy: a retrospective cohort study. Biomed Res. Int. 2021; 2021: 5572395, doi: 10.1155/2021/5572395.
11.
Duan F., Cui L., Bai Y., Li X., Yan J., Liu X. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta-analysis. Cancer Imaging 2017; 17(1): 27, doi: 10.1186/s40644-017-0129-1.
12.
Pisters P.W., Hudec W.A., Hess K.R., Lee J.E., Vauthey J.N., Lahoti S. i wsp. Effect of preoperative biliary decompression on pancreaticoduodenectomy–associated morbidity in 300 consecutive patients. Ann. Surg. 2001; 234(1): 47–55, doi: 10.1097/00000658-200107000-00008.
13.
Srivastava S., Sikora S.S., Kumar A., Saxena R., Kapoor V.K. Outcome following pancreaticoduodenectomy in patients undergoing preoperative biliary drainage. Dig. Surg. 2001; 18(5): 381–387, doi: 10.1159/000050178.
14.
Sugara M., Peruvaje V., Krishnamurthy S., Kumar K.V.V., Chowdappa R. Effect of preoperative biliary stenting on outcomes of pancreaticoduodenectomy. Indian J. Surg. Oncol. 2021; 12(3): 554–560, doi: 10.1007/s13193-021-01387-5.
15.
Baszczuk A., Kopczyński Z., Thielemann A., Musialik K., Kopczyński J., Bielawska L. i wsp. Ocena stężenia metaloproteinazy 2 (MMP-2) i meta-loproteinazy 9 (MMP-9) w surowicy chorych na pierwotne nadciśnienie tętnicze. Forum Zab. Metab. 2015; 6(2): 74–84.
16.
Wysocka A., Giziński S., Lechowski R. Metaloproteinazy macierzy – ich struktura oraz znaczenie. Życie Wet. 2014; 89(3): 223–227.
17.
Woszczycka-Korczyńska I., Górka D., Matuszek I., Pietrucha-Dutczak M., Lewin-Kowalik J. Aktywność metaloproteinaz (MMP-2, MMP-9) w odcinkach dystalnych przeciętych nerwów kulszowych dorosłych szczurów. Wiad. Lek. 2005; 58: 411–414.
18.
Trojanek J. Metaloproteinazy macierzy zewnątrzkomórkowej i ich tkankowe inhibitory. Post. Bioch. 2012; 58(3): 353–362.
19.
Medeiros N.I., Gomes J.A.S., Fiuza J.A., Sousa G.R., Almeida E.F., Novaes R.O. i wsp. MMP-2 and MMP-9 plasma levels are potential biomarkers for indeterminate and cardiac clinical forms progression in chronic Chagas disease. Sci. Rep. 2019; 9(1): 14170, doi: 10.1038/s41598-019-50791-z.
20.
Kherif S., Lafuma C., Dehaupas M., Lachkar S., Fournier J.G., Verdière-Sahuqué M. i wsp. Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles. Dev. Biol. 1999; 205(1): 158–170, doi: 10.1006/dbio.1998.9107.
21.
Zimowska M., Brzoska E., Swierczynska M., Streminska W., Moraczewski J. Distinct patterns of MMP-9 and MMP-2 activity in slow and fast twitch skeletal muscle regeneration in vivo. Int. J. Dev. Biol. 2008; 52(2–3): 307–314, doi: 10.1387/ijdb.072331mz.
22.
Frisdal E., Teiger E., Lefaucheur J.P., Adnot S., Planus E., Lafuma C., D’Ortho M.P. Increased expression of gelatinases and alteration of basement membrane in rat soleus muscle following femoral artery ligation. Neuropathol. Appl. Neurobiol. 2000; 26(1): 11–21, doi: 10.1046/j.1365-2990.2000.00210.x.
23.
Jung P., Zimowska M. Metaloproteinazy macierzy zewnątrzkomórkowej w rozwoju, fizjologii i procesach degeneracyjnych mięśni szkieletowych. Post. Bioch. 2016; 62(1): 25–35.
24.
Karowicz-Bilińska A., Kowalska-Koprek U., Estemberg D., Sikora-Szubert A. Ocena stężeń tkankowych inhibitorów metaloproteinaz TIMP-2 i TIMP-4 w III trymestrze ciąży. Ginekol. Pol. 2015; 86: 737–741, doi: 10.17772/gp/59364.
25.
Śliwowska I., Kopczyński Z. Metaloproteinazy macierzy zewnątrzkomórkowej – charakterystyka biochemiczna i kliniczna wartość oznaczania u chorych na raka piersi. Współcz. Onkol. 2005; 9(8): 327–335.
26.
Bogusiewicz M., Stryjecka-Zimmer M., Rechberger T. Aktywność metaloproteaz macierzowych -2 i -9 (MMP-2 i MMP-9) oraz zawartość ich tkankowych inhibitorów w raku błony śluzowej macicy – doniesienie wstępne. Ginekol. Pol. 2007; 78: 366–372.
27.
Pietrzak J., Wodziński D., Franiak-Pietryga I., Mirowski M. Charakterystyka elektroforetyczna aktywności metaloproteinazowej surowicy pacjentów z przewlekłą białaczką limfocytową – badania wstępne. Folia Med. Lodz. 2015; 42(1): 49–62.
28.
Chen S., Meng F., Chen Z., Tomlinson B.N., Wesley J.M., Sun G.Y. i wsp. Two-dimensional zymography differentiates gelatinase isoforms in stiulated microglial cells and in brain tissues of acute brain injuries. PLoS One 2015; 10(4): e0123852, doi: 10.1371/journal.pone.0123852.
29.
Xu F., Liu X., Wang C., Dai C. Prostaglandin E1 preconditioning attenuates liver ischemia reperfusion injury in a rat model of extrahepatic cholestasis. Biomed Res. Int. 2018; 2018: 3812424, doi: 10.1155/2018/3812424.
30.
Lin S.Y., Wang Y.Y., Chen W.Y., Liao S.L., Chou S.T., Yang C.P. i wsp. Hepatoprotective activities of rosmarinic acid against extrahepatic cholestasis in rats. Food Chem. Toxicol. 2017; 108(Pt A): 214–223, doi: 10.1016/j.fct.2017.08.005.
31.
Bebiashvili I.S., Kakabadze M.S., Gvidiani S.M., Tsomaia K.B., Gusev S.A., Kordzaia D.J. Features of ductular reaction in rats with extrahepatic cholestasis. Bull. Exp. Biol. Med. 2022; 172(6): 770–774, doi: 10.1007/s10517-022-05475-6.
32.
Zhang Z., Miao Y., Xu M., Cheng W., Yang C., She X. i wsp. TianJiu therapy for α-naphthyl isothiocyanate-induced intrahepatic cholestasis in rats treated with fresh Ranunculus sceleratus L. J. Ethnopharmacol. 2020; 248: 112310, doi: 10.1016/j.jep.2019.112310.
33.
Tylec A., Skałecki M., Kocot J., Kurzepa J. Aktywność wybranych metaloproteinaz w chorobach neurodegeneracyjnych ośrodkowego układu nerwowego na przykładzie otępienia i schizofrenii. Psychiatr. Pol. 2021; 55(6): 1221–1233, doi: 10.12740/PP/126662.
34.
Lucas-Grzelczyk W., Szemraj J., Józefowicz-Korczyńska M. Metaloproteinazy w raku krtani. Post. Hig. Med. Dośw. 2016; 70: 1190–1197.
35.
Guedes P.L., Castañon M.C., Nagaoka M.R., Aguiar J.A. Increase of glycosaminoglycans and metalloproteinases 2 and 9 in liver extracellular matrix on early stages of extrahepatic cholestasis. Arq. Gastroenterol. 2014; 51(4): 309–315, doi: 10.1590/S0004-28032014000400008.
36.
Préaux A.M., Mallat A., Nhieu J.T., D'Ortho M.P., Hembry R.M., Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999; 30(4): 944–950, doi: 10.1002/hep.510300432.
37.
Liu R., Li X., Zhu W., Wang Y., Zhao D., Wang X. i wsp. Cholangiocyte-derived exosomal long noncoding RNA H19 promotes hepatic stellate cell activation and cholestatic liver fibrosis. Hepatology 2019; 70(4): 1317–1335, doi: 10.1002/hep.30662.
38.
Cichoż-Lach H., Prozorow-Król B., Buk L., Swatek J., Celiński K., Słomka M. i wsp. Diagnostyka zmian ogniskowych wątroby – badania obrazowe czy biopsja? Doświadczenia własne. Post. Nauk Med. 2010; 1: 15–20.
39.
Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol. 2018; 68–69: 463–473, doi: 10.1016/j.matbio.2017.12.012.
40.
Yoshino K., Taura K., Iwaisako K., Masano Y., Uemoto Y., Kimura Y. i wsp. Novel mouse model for cholestasis-induced liver fibrosis resolution by cholecystojejunostomy. J. Gastroenterol. Hepatol. 2021; 36(9): 2493–2500, doi: 10.1111/jgh.15406.
41.
Gabriel A., Radłowski P., Kukla M. Odwracalność włóknienia u chorych na przewlekłe wirusowe zapalenie wątroby typu C. Cechy morfologiczne i ich ewolucja. Hepatologia 2017; 17: 72–78.
42.
Milkiewicz P. Elastografia wątroby w codziennej praktyce klinicznej. Gastroenterol. Klin. 2017; 9(1): 1–6.
43.
Lipiński P., Jankowska I. Co nowego w cholestazie – część 1. Cholestaza z prawidłową aktywnością gamma-glutamylotranspeptydazy. Pediatr. Pol. 2017; 92(4): 366–372.
44.
Feldman A.G., Sokol R.J. Recent developments in diagnostics and treatment of neonatal cholestasis. Semin. Pediatr. Surg. 2020; 29(4): 150945, doi: 10.1016/j.sempedsurg.2020.150945.
45.
Feldman A.G., Sokol R.J. Neonatal cholestasis: updates on diagnostics, therapeutics, and prevention. Neoreviews 2021; 22(12): e819–e836, doi: 10.1542/neo.22-12-e819.
46.
Zhang M., Xu M. Epigallocatechin-3-gallate ameliorates intrahepatic cholestasis of pregnancy by inhibiting matrix metalloproteinase-2 and matrix metalloproteinase-9. Fundam. Clin. Pharmacol. 2017; 31(5): 526–533, doi: 10.1111/fcp.12294.
47.
Chen Z., Shen Z., Hu L., Lu M., Feng Y. Identification of matrix metalloproteinase-2 and 9 as biomarker of intrahepatic cholestasis of pregnancy. Ann. Hepatol. 2017; 16(2): 291–296, doi: 10.5604/16652681.1231589.
48.
Lipiński P., Jankowska I. Postępująca rodzinna cholestaza wewnątrzwątrobowa typu 3. Dev. Period. Med. 2018; 22(4): 385–389, doi: 10.34763/devperiodmed.20182204.385389.
49.
Karowicz-Bilińska A. Cholestaza wewnątrzwątrobowa w ciąży. Gin. Perinat. Prakt. 2019; 4(1): 16–22.
50.
Wang X., Khalil R.A. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 2018; 81: 241–330, doi: 10.1016/bs.apha.2017.08.002.
51.
Lee M.H., Shin H..J, Yoon H., Han S.J., Koh H., Lee M.J. Periportal thickening on magnetic resonance imaging for hepatic fibrosis in infantile cholestasis. World J. Gastroenterol. 2020; 26(21): 2821–2830, doi: 10.3748/wjg.v26.i21.2821.
52.
Hozyasz K., Rowicka G. Cholestazy u dzieci. Patofizjologia, diagnostyka i leczenie. Med. Rodz. 1999; 4: 22–27.
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
